Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer
|ClinicalTrials.gov Identifier: NCT00900133|
Recruitment Status : Completed
First Posted : May 12, 2009
Last Update Posted : October 2, 2015
RATIONALE: Measuring levels of calgranulin A and calgranulin B in the blood of patients with breast cancer in the laboratory may help doctors identify and learn more about biomarkers related to breast cancer.
PURPOSE: This laboratory study is measuring calgranulin A and calgranulin B levels in the blood of patients with newly diagnosed stage I, stage II, or stage III breast cancer.
|Condition or disease||Intervention/treatment|
|Breast Cancer||Other: immunoenzyme technique Other: laboratory biomarker analysis|
- Determine circulating levels of calgranulin A and calgranulin B in patients with estrogen receptor negative or estrogen receptor positive, newly diagnosed, primary stage I-III adenocarcinoma of the breast.
OUTLINE: This is a pilot study.
Patients undergo a blood draw following diagnosis of breast cancer to assess levels of circulating tumor markers, calgranulin A and calgranulin B. Serum samples are evaluated by enzyme-linked immunosorbent assay for tumor marker expression.
PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
|Study Type :||Observational|
|Actual Enrollment :||60 participants|
|Official Title:||A Pilot Trial to Correlate Serum Levels of Calgranulin A and B With Estrogen Receptor Status Among Patients With Breast Cancer|
|Study Start Date :||January 2005|
|Primary Completion Date :||April 2006|
|Study Completion Date :||December 2006|
Other: immunoenzyme technique
- Correlation between circulating levels of calgranulin A and calgranulin B and the presence of estrogen receptor negative breast cancer [ Time Frame: upon diagnosis ]
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00900133
|United States, Ohio|
|Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center|
|Cleveland, Ohio, United States, 44106|
|Principal Investigator:||John Pink, PhD||Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center|